Insider Transactions Reported by 24 Insiders of Traws Pharma, Inc.

Symbol
TRAW on Nasdaq
Location
Newtown, PA

Quick Takeaways

  • TRAW - Traws Pharma, Inc. has 24 insiders with reported activity on this page.
  • No net insider buy/sell flow is currently reported for the last year.
  • Recent transaction rows are available for direct filing-level review.

What Changed

  • No meaningful buy/sell imbalance is currently visible in the one-year window.
  • Activity will update as new Forms 3/4/5 are filed.

Why This Matters

  • This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
  • Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 19 Apr 2025.

Buys

$0

Shares: 0

Insiders: 0

Sells

$0

Shares: 0

Insiders: 0

Net

$0

Shares: 0

Insiders: 0

Window (months) Buy shares Sell shares Buy $ Sell $ Net $
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Traws Pharma, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Viriom, Inc. 10%+ Owner $1,480,590 Mixed 03 Apr 2024
Iain D. Dukes Chief Executive Officer, Director $438,092 Mixed 08 Mar 2026
Nikolay Savchuk Chief Operating Officer, Director $385,551 Mixed 08 Mar 2026
Charles D. Pauza Chief Science Officer Virology $296,885 Mixed 08 Mar 2026
Robert Redfield Chief Medical Officer $291,632 Mixed 08 Mar 2026
ORBIMED ADVISORS LLC 10%+ Owner $282,940 Mixed 29 Dec 2024
Werner Cautreels Director $279,608 Mixed 08 Mar 2026
Steven M. Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF, Director $98,282 Mixed 13 Mar 2024
Abraham N. Oler SVP Corp Dev & Gen Counsel $36,818 Mixed 07 Feb 2022
Charles N. Parker Chief Financial Officer $24,628 Mixed 12 Oct 2025
Mark Patrick Guerin Chief Financial Officer $23,400 Mixed 05 Feb 2025
Mary Teresa Shoemaker Director $16,107 Mixed 08 Mar 2026
Jack E. Stover Director $15,782 Mixed 08 Mar 2026
Trafford Clarke Director $15,761 Mixed 08 Mar 2026
Mark S. Gelder MD Chief Medical Officer $13,847 Mixed 13 Mar 2023
John H. Leaman Director $10,388 Mixed 08 Mar 2026
TPAV, LLC 10%+ Owner $0 Mixed 02 Apr 2025
Jerome Groopman Director Mixed 10 Aug 2023
Victor M. Moyo Chief Medical Officer Mixed 02 Oct 2023
Viren Mehta Director Mixed 10 Aug 2023
James J. Marino Director Mixed 10 Aug 2023
Peter Atadja Director Mixed 10 Aug 2023
Nora Brennan Interim CFO Mixed 05 Feb 2025
Luba Greenwood Director Mixed 16 Sep 2024

Top shareholders of Traws Pharma, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
PERCEPTIVE ADVISORS LLC
13D/G
—
10%
886,887
 $1,641,628 +$632,468 30 Sep 2025
13D/G
Viriom, Inc.
3/4/5
10%+ Owner —
class O/S missing
1,645,100
 $1,480,590 — 03 Apr 2024
3/4/5
Ikarian Capital, LLC
13D/G 13F
Company
10%
812,524
 $1,308,164 +$359,065 31 Dec 2025
13D/G 13F
Adage Capital Management, L.P.
13D/G
—
9.1%
730,000
 $1,175,300 +$644,000 31 Dec 2025
13D/G
ORBIMED ADVISORS LLC
13D/G 3/4/5 13F
10%+ Owner · Company
20%
760,824
 $1,164,061 $0 31 Dec 2024
13D/G 3/4/5 13F
Squadron Capital Management LLC
13D/G 13F
Squadron Master Fund LP · Company
8.9%
713,540
 $1,148,799 +$197,289 31 Dec 2025
13D/G 13F
ADAGE CAPITAL PARTNERS GP, L.L.C.
13F
Company
9%
730,000
 $824,900 — 31 Dec 2025
13F
Jorey Chernett
13D/G
Chernett Jorey
6.8%
543,268
 $668,220 $0 14 Jan 2026
13D/G
Ayrton Capital LLC
13D/G
—
4.3%
342,935
 $552,125 -$97,751 31 Dec 2025
13D/G
Alyeska Investment Group, L.P.
13D/G
—
9.9%
302,252
 $462,446 $0 31 Dec 2024
13D/G
Iain D. Dukes
3/4/5
Chief Executive Officer, Director —
mixed-class rows
550,237
mixed-class rows
 $438,092 — 08 Mar 2026
3/4/5
Nikolay Savchuk
3/4/5
Chief Operating Officer, Director —
mixed-class rows
313,181
mixed-class rows
 $385,551 — 08 Mar 2026
3/4/5
Charles D. Pauza
3/4/5
Chief Science Officer Virology —
mixed-class rows
308,224
mixed-class rows
 $296,885 — 08 Mar 2026
3/4/5
Robert Redfield
3/4/5
Chief Medical Officer —
mixed-class rows
288,449
mixed-class rows
 $291,632 — 08 Mar 2026
3/4/5
Werner Cautreels
3/4/5
Director —
mixed-class rows
159,976
mixed-class rows
 $279,608 — 08 Mar 2026
3/4/5
BOOTHBAY FUND MANAGEMENT, LLC
13F
Company
2.4%
194,536
 $219,826 — 31 Dec 2025
13F
ADAR1 Capital Management, LLC
13F
Company
1.9%
154,431
 $174,507 — 31 Dec 2025
13F
VANGUARD GROUP INC
13F
Company
1.1%
87,259
 $98,603 — 31 Dec 2025
13F
Steven M. Fruchtman
3/4/5
PRESIDENT, CHIEF EXECUTIVE OFF, Director —
mixed-class rows
121,014
mixed-class rows
 $98,282 — 13 Mar 2024
3/4/5
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.76%
61,653
 $69,668 — 31 Dec 2025
13F
Seven Fleet Capital Management LP
13F
Company
0.61%
49,260
 $55,664 — 31 Dec 2025
13F
XTX Topco Ltd
13F
Company
0.52%
42,210
 $47,697 — 31 Dec 2025
13F
Abraham N. Oler
3/4/5
SVP Corp Dev & Gen Counsel —
mixed-class rows
96,197
mixed-class rows
 $36,818 — 07 Feb 2022
3/4/5
STATE STREET CORP
13F
Company
0.32%
25,802
 $29,156 — 31 Dec 2025
13F
CITADEL ADVISORS LLC
13F
Company
0.31%
24,819
 $28,045 — 31 Dec 2025
13F
Charles N. Parker
3/4/5
Chief Financial Officer —
mixed-class rows
119,937
mixed-class rows
 $24,628 — 12 Oct 2025
3/4/5
Mark Patrick Guerin
3/4/5
Chief Financial Officer —
mixed-class rows
44,755
mixed-class rows
 $23,400 — 05 Feb 2025
3/4/5
TWO SIGMA INVESTMENTS, LP
13F
Company
0.24%
19,244
 $21,746 — 31 Dec 2025
13F
Mary Teresa Shoemaker
3/4/5
Director —
mixed-class rows
64,356
mixed-class rows
 $16,107 — 08 Mar 2026
3/4/5
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
0.17%
14,197
 $16,043 — 31 Dec 2025
13F
Jack E. Stover
3/4/5
Director —
mixed-class rows
64,229
mixed-class rows
 $15,782 — 08 Mar 2026
3/4/5
Trafford Clarke
3/4/5
Director —
mixed-class rows
64,221
mixed-class rows
 $15,761 — 08 Mar 2026
3/4/5
Mark S. Gelder MD
3/4/5
CHIEF MEDICAL OFFICER —
mixed-class rows
82,667
mixed-class rows
 $13,847 — 13 Mar 2023
3/4/5
BlackRock, Inc.
13F
Company
0.12%
9,956
 $11,250 — 31 Dec 2025
13F
John H. Leaman
3/4/5
Director —
mixed-class rows
53,727
mixed-class rows
 $10,388 — 08 Mar 2026
3/4/5
UBS Group AG
13F
Company
0.09%
7,722
 $8,726 — 31 Dec 2025
13F
SBI Securities Co., Ltd.
13F
Company
0%
162
 $183 — 31 Dec 2025
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
113
 $128 — 31 Dec 2025
13F
OSAIC HOLDINGS, INC.
13F
Company
0%
8
 $9 — 31 Dec 2025
13F
FMR LLC
13F
Company
0%
2
 $2 — 31 Dec 2025
13F
CITIGROUP INC
13F
Company
0%
1
 $1 — 31 Dec 2025
13F
TPAV, LLC
3/4/5
10%+ Owner —
mixed-class rows
192,696
mixed-class rows
 — — 02 Apr 2025
3/4/5
Luba Greenwood
3/4/5
Director —
class O/S missing
164,000
 — — 16 Sep 2024
3/4/5
Victor M. Moyo
3/4/5
CHIEF MEDICAL OFFICER —
class O/S missing
125,000
 — — 02 Oct 2023
3/4/5
James J. Marino
3/4/5
Director —
class O/S missing
66,468
 — — 10 Aug 2023
3/4/5
Jerome Groopman
3/4/5
Director —
class O/S missing
66,468
 — — 10 Aug 2023
3/4/5
Peter Atadja
3/4/5
Director —
class O/S missing
66,468
 — — 10 Aug 2023
3/4/5
Viren Mehta
3/4/5
Director —
class O/S missing
66,468
 — — 10 Aug 2023
3/4/5

Recent Insider Transactions by Companies or Individuals for Traws Pharma, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
Charles N. Parker TRAW Stock Option (right to buy) Award 104,544 104,544 08 Mar 2026 Direct
Trafford Clarke TRAW Stock Option (right to buy) Award 33,435 33,435 08 Mar 2026 Direct
Werner Cautreels TRAW Stock Option (right to buy) Award 31,258 31,258 08 Mar 2026 Direct
John H. Leaman TRAW Stock Option (right to buy) Award 33,435 33,435 08 Mar 2026 Direct
Iain D. Dukes TRAW Stock Option (right to buy) Award 231,336 231,336 08 Mar 2026 Direct
Charles D. Pauza TRAW Stock Option (right to buy) Award 118,367 118,367 08 Mar 2026 Direct
Nikolay Savchuk TRAW Stock Option (right to buy) Award 96,899 96,899 08 Mar 2026 Direct
Jack E. Stover TRAW Stock Option (right to buy) Award 33,435 33,435 08 Mar 2026 Direct
Robert Redfield TRAW Stock Option (right to buy) Award 108,854 108,854 08 Mar 2026 Direct
Mary Teresa Shoemaker TRAW Stock Option (right to buy) Award 33,435 33,435 08 Mar 2026 Direct
Charles N. Parker TRAW Common Stock Award 15,393 15,393 12 Dec 2025 Direct
Charles N. Parker TRAW Stock Option (right to buy) Award 61,571 61,571 12 Dec 2025 Direct
John Harold Leaman TRAW Common Stock Award 4,058 4,058 12 Dec 2025 Direct
John Harold Leaman TRAW Stock Option (right to purchase) Award 16,234 16,234 12 Dec 2025 Direct
Trafford Clarke TRAW Common Stock Award 6,157 6,157 12 Dec 2025 Direct
Trafford Clarke TRAW Stock Option (right to purchase) Award 24,629 24,629 12 Dec 2025 Direct
Werner Cautreels TRAW Common Stock Award 4.67% 4,874 109,222 12 Dec 2025 Direct
Werner Cautreels TRAW Stock Option (right to purchase) Award 19,496 19,496 12 Dec 2025 Direct
Mary Teresa Shoemaker TRAW Common Stock Award 4560.7% 6,157 6,292 12 Dec 2025 Direct
Mary Teresa Shoemaker TRAW Stock Option (right to purchase) Award 24,629 24,629 12 Dec 2025 Direct
Jack E. Stover TRAW Common Stock Award 76962.5% 6,157 6,165 12 Dec 2025 Direct
Jack E. Stover TRAW Stock Option (right to purchase) Award 24,629 24,629 12 Dec 2025 Direct
Iain D. Dukes TRAW Common Stock Award 27.5% 36,943 171,130 12 Dec 2025 Direct
Iain D. Dukes TRAW Stock Option (right to purchase) Award 147,771 147,771 12 Dec 2025 Direct
Charles David Pauza TRAW Common Stock Award 18.9% 18,471 115,971 12 Dec 2025 Direct
Charles David Pauza TRAW Stock Option (right to purchase) Award 73,886 73,886 12 Dec 2025 Direct
Robert Redfield TRAW Common Stock Award 16.8% 16,419 113,919 12 Dec 2025 Direct
Robert Redfield TRAW Stock Option (right to purchase) Award 65,676 65,676 12 Dec 2025 Direct
Nikolay Savchuk TRAW Common Stock Award 12.2% 16,419 150,606 12 Dec 2025 Direct
Nikolay Savchuk TRAW Stock Option (right to purchase) Award 65,676 65,676 12 Dec 2025 Direct
John Harold Leaman TRAW Stock Option (right to purchase) Award 12,770 12,770 21 Nov 2025 Direct
Charles N. Parker TRAW Stock Option (right to buy) Award 32,406 32,406 12 Oct 2025 Direct
Nikolay Savchuk TRAW Stock Option (right to purchase) Award 22,435 22,435 12 Oct 2025 Direct
Robert Redfield TRAW Stock Option (right to purchase) Award 32,406 32,406 12 Oct 2025 Direct
Charles David Pauza TRAW Stock Option (right to purchase) Award 32,406 32,406 12 Oct 2025 Direct
Iain D. Dukes TRAW Stock Option (right to purchase) Award 64,839 64,839 12 Oct 2025 Direct
Werner Cautreels TRAW Stock Option (right to purchase) Award 11,530 11,530 12 Oct 2025 Direct
Jack E. Stover TRAW Stock Option (right to purchase) Award 11,530 11,530 12 Oct 2025 Direct
Trafford Clarke TRAW Stock Option (right to purchase) Award 11,530 11,530 12 Oct 2025 Direct
Mary Teresa Shoemaker TRAW Stock Option (right to purchase) Award 11,530 11,530 12 Oct 2025 Direct
John Harold Leaman TRAW Stock Option (right to purchase) Award 15,609 15,609 01 Oct 2025 Direct
Trafford Clarke TRAW Stock Option (right to purchase) Award 23,000 23,000 19 Jun 2025 Direct
Jack E. Stover TRAW Stock Option (right to purchase) Award 23,000 23,000 19 Jun 2025 Direct
Mary Teresa Shoemaker TRAW Stock Option (right to purchase) Award 23,000 23,000 19 Jun 2025 Direct
Werner Cautreels TRAW Stock Option (right to purchase) Award 23,000 23,000 19 Jun 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.